Table: Astellas -9-MTH group results (IFRS)

Astellas Pharma

04/02/2025 06:31

Feb 4 (Reuters)- 
              Astellas Pharma Inc. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   9 months ended      9 months ended       Year to 
                  Dec 31, 2024        Dec 31, 2023     Mar 31, 2025 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales             1.45 trln           1.19 trln        1.90 trln  
                   (+22.2 pct)         (+2.1 pct)       (+18.5 pct) 
  Operating        loss 22.48             74.12            11.00    
                                       (-59.1 pct)      (-56.9 pct) 
  Pretax           loss 29.32             73.63             1.00    
                                       (-59.1 pct)      (-96.0 pct) 
  Net              loss 24.15             50.32            14.00    
                                       (-65.3 pct)      (-17.9 pct) 
  EPS Basic      loss 13.49 yen         28.06 yen        7.82 yen   
  EPS Diluted    loss 13.49 yen         27.96 yen                   
  Ann Div                               70.00 yen        74.00 yen  
  -Q2 Div           37.00 yen           35.00 yen                   
  -Q4 Div                               35.00 yen        37.00 yen  
 
  NOTE - Astellas Pharma Inc.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4503.T